British American Tobacco (LSE: BATS) share price: what to know before the London open on 17 November 2025

Summary at a glance

Last close (Fri, 14 Nov): 4,072p on the LSE. Next dividend ex‑date: 29 Dec 2025 (60.06p), with the most recent quarterly payout (also 60.06p) paid on 7 Nov 2025. ^[1]
Overnight read‑across: BAT’s U.S. ADR (NYSE: BTI) finished Friday at $54.13, a mild negative cue for London. ^[2]
Capital moves: BAT issued €1.2bn of hybrid capital in late October and launched a tender offer for its 2021 euro hybrid—steps that bolster balance‑sheet flexibility. ^[3]
Guidance snapshot: Management is targeting 1–2% FY25 revenue growth and 1.5–2.5% adjusted profit from operations growth, with £1.1bn of buybacks this year and FX headwinds (c. 4% translational and 1.5% transactional). ^[4]
Near‑term catalysts: BAT’s Full‑Year 2025 pre‑close trading update is scheduled for 9 Dec 2025. ^[5]

Where BATS left off on Friday

British American Tobacco shares closed at 4,072p on 14 November. BAT’s official tear‑sheet also shows the latest dividend timetable: the November instalment was paid on 7 Nov 2025 (ex‑date 2 Oct), and the next ex‑date is 29 Dec 2025 for payment on 4 Feb 2026—useful for investors positioning into year‑end. ^[6]

Overnight sentiment from New York is slightly softer: the ADR BTI finished Friday at $54.13. While the ADR is not a perfect predictor of the LSE open, it often provides a directional cue for early trading in London. ^[7]

The news that matters before the bell

1) Balance‑sheet moves: hybrids issued, an older hybrid targeted

BAT published a prospectus on 28 October for a €1.2bn dual‑tranche hybrid capital issue (perpetual NC5.25 and NC8), which counts as equity under IFRS and typically receives 50% equity credit from agencies. A week earlier, the company invited holders of its €1bn 2021 NC5.25 hybrid (3.00%) to tender the notes for cash. Together, the transactions refresh the hybrid layer and can lower future refinancing risk. ^[8]

2) 2025 guidance & buybacks: what the company is signalling

In its first‑half pre‑close update, BAT said it expects 1–2% group revenue growth and 1.5–2.5% adjusted profit from operations growth for FY25 at constant FX, with a £1.1bn “sustainable share buy‑back” this year. Management also flagged currency as a drag (~4% translational and ~1.5% transactional headwinds) and reiterated a deleveraging corridor of 2.0–2.5x net debt/adjusted EBITDA by end‑2026. These are the numbers the market will trade against into December’s pre‑close. ^[9]

3) U.S. backdrop: regulatory overhang eased in 2025, but competition in vapes tightened

Menthol ban: In January, the new U.S. administration withdrew the FDA’s plan to ban menthol cigarettes, removing a major overhang for U.S. combustibles that had worried the market since 2022. ^[10]
Graphic warnings: A U.S. federal judge blocked the FDA’s graphic‑warning rule (effective date delayed into 2026 pending litigation), reducing near‑term packaging risk for R.J. Reynolds, BAT’s U.S. unit. ^[11]
Juul authorization: The FDA authorized Juul’s tobacco and menthol e‑cigarette products in July, a competitive development for BAT’s Vuse in the crucial U.S. vapour market. ^[12]
Tariffs: BAT noted that Vuse devices made in Indonesia are subject to a 19% tariff, but said most of the impact could be absorbed in margins, with some inventory pre‑positioned. ^[13]

4) Operations & trading: H1 recovery in the U.S., New Categories still scaling

BAT’s H1 2025 profit topped estimates, with U.S. revenues up 3.7% (constant FX)—the first increase there in three years—while smokeless products represented 18%+ of group revenue. Management highlighted strong momentum in Velo (modern oral), continued global share leadership in Vuse, and a plan to accelerate glo (heated products) roll‑outs into H2. ^[14]

5) Canada litigation: settlement progress already reflected in numbers

In March, a Canadian court approved BAT’s contribution to a national product‑liability settlement. BAT had flagged a £6.2bn provision related to Canada earlier in the year; the update reduced tail risk and clarified cash‑out timing. The company now reports selected figures on an “adjusted for Canada” basis to avoid distortion. ^[15]

6) Governance: CFO change in August

BAT announced in late August that CFO Soraya Benchikh stepped down after ~15 months; Javed Iqbal returned as interim CFO while the search for a permanent successor proceeds. Investors will watch for any capital‑allocation changes ahead of December’s pre‑close and into FY results. ^[16]

7) UK policy watch: generational smoking bill still moving through Parliament

The UK Tobacco and Vapes Bill—which would create a “smoke‑free generation” and tighten vape rules—continued its passage in 2025, with Lords committee stage activity reported in late October. The path and timing remain important for domestic cigarette volumes and UK vape retailing, although effects would phase in over time. ^[17]

8) ESG headlines

Late last week, The Guardian reported criticism of BAT’s lobbying stance in Zambia versus UK standards—an item that may not shift cash flows but can influence ESG screening and sentiment. ^[18]

What to watch at the open on Monday

ADR read‑across vs FX: Slight softness in BTI ($54.13) is a gentle headwind; watch GBP/USD in early trade given BAT’s FX sensitivity (translational ~4% and transactional ~1.5% headwind in FY25 guidance). ^[19]
Buyback support: The £1.1bn 2025 buyback provides an incremental bid for shares—traders often look for its footprint on lower‑liquidity days. ^[20]
Debt & hybrids: The hybrid issuance and associated tender offer are balance‑sheet positives; any follow‑on documentation or pricing updates could nudge the equity narrative. ^[21]
U.S. vapour headlines: With Juul back on shelves and illicit disposables still a factor, any U.S. enforcement or competitive newsflow can ripple into expectations for Vuse. ^[22]
Calendar: Build positions with 9 Dec in mind (pre‑close update) as the next set‑piece event for 2025 guidance fine‑tuning. ^[23]

Dividend & valuation context

BAT remains a quarterly payer, with the current series set at 60.06p per share. The next ex‑date is 29 Dec 2025 (LSE: 29 Dec; NYSE ADR timeline follows a day later), and the payment date is 4 Feb 2026. Investors who held for the 7 Nov 2025 payment already captured the third instalment. These dates can influence near‑term flows as income funds rebalance into year‑end. ^[24]

Bottom line for Monday

There is no single fresh company‑specific shock over the weekend.
The ADR cue is modestly negative, but buybacks, stabilising U.S. trends, and a lighter U.S. regulatory overhang should help frame sentiment into December’s update.
Keep an eye on FX, vapour competition, and any RNS in the 07:00 window that could reset expectations intraday. ^[25]

Sources & further reading

LSE tear‑sheet & dividend timetable: prior close 4,072p; ex‑dates and payments. ^[26]
ADR close (BTI): $54.13 (Fri, 14 Nov). ^[27]
BAT 2025 H1 pre‑close update (guidance, FX, buyback): 3 Jun 2025. ^[28]
Hybrids & tender offer: RNS 28 Oct 2025 (prospectus) and 21 Oct 2025 (tender invitation). ^[29]
H1 2025 trading beat & tariff commentary: Reuters, 31 Jul 2025. ^[30]
U.S. menthol rule withdrawn: Reuters, 24 Jan 2025. ^[31]
U.S. graphic warnings blocked: Reuters, 14 Jan 2025. ^[32]
Canada settlement approved: Reuters, 7 Mar 2025 (context on £6.2bn provision also covered by FT). ^[33]
CFO change: Reuters, 26 Aug 2025. ^[34]
UK Tobacco & Vapes Bill progress: Commons Library brief & ASH update. ^[35]
ESG headline (Zambia): The Guardian, 13 Nov 2025. ^[36]

This article is for information only and is not investment advice. Always do your own research and consider your objectives and risk tolerance before acting on market information.

HOW TO GET RICH WITH INVESTING